CookSWeitzmanMAuingerP. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey 1988–1994. Archives of Pediatrics & Adolescent Medicine2003; 157: 821–827.
2.
CorrellCUCarlsonHE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry2006; 45: 771–791.
3.
CorrellCU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. Journal of the American Academy of Child and Adolescent Psychiatry2007; 46: 687–700.
4.
PatelNCHariparsadMMatias-AktharM. Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics. Journal of Child and Adolescent Psychopharmacology2007; 17: 303–311.
5.
PanagiotopoulosCRonsleyRDavidsonJ. Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications. Canadian Journal of Psychiatry2009; 54:743–749.
6.
HedleyAAOgdenCLJohnsonCL. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. JAMA: the Journal of the American Medical Association2004; 291: 2847–2850.
7.
HetrickSAlvarez-JiménezMParkerA. Promoting physical health in youth mental health services: ensuring routine monitoring of weight and metabolic indices in a first episode psychosis clinic. Australasian Psychiatry2010; 18: 451–455.
8.
WalterGDeLarocheASohN. Side effects of second-generation antipsychotics: the experience, views and monitoring practices of Australian child psychiatrists. Australasian Psychiatry2008; 16: 253–262.
